Loading
A phase 3 trial of Fulzerasib, Garsorasib and Glecirasib in Non-small-cell lung cancer, run by Shandong Suncadia Medicine Co., Ltd., not yet recruiting.
A Trial of HRS-7058 in Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment is a phase 3 interventional study registered as NCT07601048 by Shandong Suncadia Medicine Co., Ltd., with 450 participants planned, started 2026-06 and due to reach its primary completion in 2028-05. Interventions recorded: HRS-7058, Fulzerasib Tablets, Garsorasib Tablets, Glecirasib Citrate Tablets. Conditions recorded: KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment.
Linked to the drug Fulzerasib because the registry names it among its interventions and Non-small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Fulzerasib, KRAS G12C-mutant non-small-cell lung cancer and the tag pipeline.
Shares Glecirasib, KRAS G12C-mutant non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals, Non-small-cell lung cancer and the tag pipeline.
Shares Garsorasib, KRAS G12C-mutant non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Fulzerasib and the tag pipeline.
Shares KRAS G12C-mutant non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares KRAS G12C-mutant non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Garsorasib and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/